Semaglutide evidence, regulatory status, intended use, known risks, and limitations.
Regulatory status
FDA-approved drug for product-specific indications
Quick verdict
An evidence-backed prescription option for its specific FDA-approved indication. Individual decisions require a licensed clinician.
At a glance
Primary use: Chronic weight management and other labeled uses vary by product. Evidence strength: Strong — FDA-reviewed clinical program. Prescription treatment and clinician supervision are required.
What it is
Semaglutide is a GLP-1 receptor agonist available in FDA-approved products with product-specific indications. Approval should not be generalized to every formulation or use.
What it’s used for
Chronic weight management and other labeled uses vary by product
How it works
Mechanism and pharmacology are described in the current FDA prescribing information; this review does not provide dosing instructions.
Clinical evidence
Strong — FDA-reviewed clinical program. Public claims on this page are limited to the cited regulatory and clinical evidence.
FDA / Regulatory status
FDA-approved drug for product-specific indications
Administration
Weekly injection or daily oral tablet, depending on the approved product. Prescription required. Availability, formulary coverage, prior authorization, and patient cost vary by product and plan. Novo Nordisk publicly lists Wegovy at $1,349.02 per package and documents eligibility-limited savings/self-pay support; this is not a guaranteed out-of-pocket price. No FDA-approved generic semaglutide was confirmed in this review.
Potential benefits
FDA-reviewed evidence supports product-specific benefits for labeled indications.
Known risks & side effects
FDA labeling includes a boxed warning about thyroid C-cell tumors observed in rodents and warnings addressing pancreatitis, gallbladder disease, kidney injury related to volume depletion, and severe gastrointestinal reactions.
Contraindications / Important warnings
FDA labeling includes a boxed warning about thyroid C-cell tumors observed in rodents and warnings addressing pancreatitis, gallbladder disease, kidney injury related to volume depletion, and severe gastrointestinal reactions.
Who it may be appropriate for
Potentially appropriate only for patients who meet product-specific labeled criteria after clinician assessment.
Evidence gaps
Compounded semaglutide is not an FDA-approved finished product.
Alternatives
Review established options for the relevant goal and discuss clinically appropriate alternatives with a licensed professional.
Score breakdown
Editorial score 9.1/10 — Clinical Evidence 9.5; Regulatory Status 10; Effectiveness Evidence 9.5; Safety / Known Risks 7.5; Access & Convenience 8; Cost Transparency 8.5. Weighted using the published methodology.
Final verdict
A legitimate prescription therapy for specific approved uses, with important product-specific risks and limitations.
MyPeptideQuest
Information only. Not medical advice. No dosing or self-treatment instructions are provided.